健康元：玛帕西沙韦胶囊获药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for its innovative antiviral drug, Marpaviroc Capsules, aimed at treating influenza in healthy adolescents and adults aged 12 and above [1] Group 1 - The drug Marpaviroc Capsules (Yilikan) is classified as a Class 1 new drug for influenza treatment [1] - The approved indication is for the treatment of uncomplicated influenza A and B in previously healthy patients aged 12 and older [1] - The drug is not indicated for patients at high risk of complications related to influenza [1]